

Subject: Medical Science Liaison (MSL) Notes - Introduction of GastroGuard

Date: May 10, 2026

Provider: Dr. Emily Chanmugam

Title: Oncologist

Institution: GastroOncology Institute

Summary of Key Discussion Points:

1. Introduction:

- Introduced GastroGuard as an innovative therapy for advanced gastric cancer.
- Emphasized its unique targeted mechanism aiming to inhibit tumor growth and improve overall survival.

2. Provider's Current Patient Cases:

- Dr. Chang expressed interest in new treatment options for gastric cancer, particularly those offering improved efficacy and reduced side effects.
- Discussed specific cases where current treatments have shown limitations in disease control and tolerability.

3. Efficacy and Clinical Data:

- Presented recent clinical data showcasing GastroGuard's ability to extend progression-free survival and overall survival in advanced gastric cancer patients.
- Highlighted statistically significant improvements in response rates compared to standard-of-care treatments.

4. Safety Profile:

- Discussed the favorable safety profile of GastroGuard, with manageable and well-tolerated adverse effects in late-phase trials.
- Dr. Chang inquired about specific adverse events observed and any considerations for managing them in clinical practice.

5. Mechanism of Action:

- Provided a detailed explanation of GastroGuard's mechanism, focusing on its targeted inhibition of specific molecular pathways implicated in gastric cancer.
- Dr. Chang appreciated the detailed explanation and sought insights into potential benefits for patients with specific genetic mutations.

6. Patient Adherence and Education:

- Discussed strategies for enhancing patient adherence to GastroGuard through a once-daily oral tablet.
- Shared patient education materials emphasizing the importance of regular follow-ups and potential supportive care measures.

7. Emerging Research and Future Developments:

- Highlighted ongoing research on GastroGuard's potential in adjuvant and neoadjuvant settings for gastric cancer.
- Discussed plans for exploring combination therapies to tailor treatment plans for patients with diverse disease presentations.

8. Competitive Landscape:

- Compared GastroGuard to existing therapies for advanced gastric cancer, emphasizing its unique mechanism and potential for improved outcomes.
- Discussed the challenges of managing advanced gastric cancer and the need for a multidisciplinary approach in treatment decisions.

9. Access and Reimbursement:

- Provided updates on access and reimbursement programs for oncology clinics.
- Dr. Chang expressed concerns about potential affordability barriers for patients and the need for patient assistance programs.

10. Action Items and Follow-Up:

- Dr. Chang expressed interest in incorporating GastroGuard into her practice for specific patient subgroups.
- Agreed upon a follow-up in three months to discuss initial patient responses and address any emerging concerns.

11. Closing Remarks:

- Expressed gratitude for Dr. Chang's dedication to advancing gastric cancer care.
- Reiterated commitment to ongoing collaboration and support for the GastroOncology Institute.